Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interferon beta as a therapy for múltiple sclerosis]

F Zaragozá García1, M Ibarra Lorente

  • 1Departamento de Farmacología. Universidad de Alcalá. Madrid. Spain.

Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria
|February 22, 2003
PubMed
Summary

Interferon beta treatments for multiple sclerosis (MS) are effective at reducing relapses. Current evidence suggests similar efficacy across available products, with no clear benefit from higher doses or increased frequency beyond standard Phase III trial levels.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Listening to transform: Impact of patient experience on the improvement of an outpatient pharmacy unit.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2026
Same journal

MAPEX-SEFH guide for the implementation of patient-reported outcomes and experience in outpatient hospital pharmacy.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2026
Same journal

Concordance between the theoretical and real stratification of the ability-motivation-opportunity model in patients with cardiovascular pathologies.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2026
Same journal

[Translated article] Real-world evidence of immune-related adverse events as predictive factor of response in non-small cell lung cancer.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2026
Same journal

[Translated article] Safety of excipients in pediatric medications: impact on child health.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2026
Same journal

[Translated article] Computerized gravimetric control of parenteral analgesic admixtures: A retrospective quality improvement study.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2026

Area of Science:

  • Neuroimmunology
  • Pharmacology

Background:

  • Interferon beta (IFN-beta) has significantly advanced multiple sclerosis (MS) treatment.
  • IFN-beta therapies reduce relapse rates and severity and improve MRI-measured disease parameters.
  • Controversy exists regarding optimal dosing, administration routes, and frequency for IFN-beta in MS.

Purpose of the Study:

  • To review existing studies on the efficacy of current interferon beta products for MS.
  • To evaluate evidence supporting or refuting a dose-effect relationship for IFN-beta in MS treatment.
  • To provide insights into optimal interferon beta administration strategies for multiple sclerosis.

Main Methods:

  • Systematic review of clinical trials and published studies on interferon beta for multiple sclerosis.
  • Analysis of data comparing efficacy across different IFN-beta formulations.

Related Experiment Videos

  • Examination of evidence regarding dose-response relationships in interferon beta therapy.

    • Main Results:

    • Available data suggest comparable efficacy among the three main interferon beta products for MS.
    • Clinical trial design differences complicate direct comparisons of efficacy.
    • No strong evidence supports improved efficacy with increased doses or frequency beyond Phase III trial parameters.

    Conclusions:

    • Current interferon beta therapies offer similar efficacy for multiple sclerosis management.
    • Increasing dose or frequency of administration beyond established Phase III trial levels is unlikely to yield significant additional clinical benefit.
    • Further research may be needed to refine optimal interferon beta treatment protocols for MS.